09 october 2023
Post-processing artificial intelligence (Al)-powered software intended to measure bone mineral density, robot-assisted joint replacements to analyze X-rays and flagging anomalies, innovative diagnostics-integrated biosensors: these are a few examples of advanced solutions that boost the MedTech market, open the doors to the use of artificial intelligence (AI) and machine learning (ML), that will become a primary driver of medical device innovation globally.
These improvements in the biomedical domain are gaining significant interest and hold considerable potential for the future of healthcare, particularly in the context of in vitro diagnostics. The European Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR) explicitly include software in their requirements. This poses significant challenges for IVDs and MDs that involve Machine Learning (ML) algorithms for data analysis and decision support.
The potential of these new technologies is not only to diagnose but also to mitigate or prevent severe disease. AI-based IVDs can potentially improve healthcare decision-making in the coming years exponentially.
In Europe, there are currently no laws or harmonized standards that specifically regulate the use of AI in medical devices. However, these devices must meet existing regulatory requirements, such as:
The European Union is working on a proposed AI regulation (called “AI Act”) that aims to significantly bolster regulations on the development and use of artificial intelligence and focuses primarily on strengthening rules around safety, data quality (such as transparency, traceability, and non-discriminatory), human oversight, and accountability. Once approved, the “AI Act” will be the world’s first official legislation on AI. On June 14th, 2023, the EU member states an agreement on the proposal is expected by the end of this year.
In parallel, the US Food and Drug Administration (FDA), together with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Canada, have jointly identified ten (10) guiding principles related to the development of Good Machine Learning Practice (GMLP). These guiding principles will help promote safe, effective, high-quality medical devices using artificial intelligence and machine learning (AI/ML).
The ten (10) guiding principles are as follows:
Some Initiatives are carried out into other regulatory platforms to bring AI capabilities to innovative medical devices,
As we stand at the threshold of a new era, the MedTech industry finds itself on the brink of remarkable transformation. From groundbreaking advancements in medical devices and diagnostics to the convergence of technology and healthcare, the future holds immense promise and potential.
PLG will continue to expand its team of experts to support customers in a flexible, customized, yet cost-efficient way. Please find out how we can support you in placing your innovative device on the market: contact us here.
Go to our Events to register
Go to our News to get insights